Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension

STUDY OBJECTIVES: Esmirtazapine (1.5–4.5 mg) has demonstrated short-term sleep-promoting effects in nonelderly outpatients with chronic insomnia. This phase 3, randomized, double-blind study (NCT00631657) and its open-label extension (NCT00750919) investigated efficacy and safety of long-term esmirt...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Sleep Med
Hlavní autoři: Ivgy-May, Neely, Hajak, Goeran, van Osta, Gonnie, Braat, Sabine, Chang, Qing, Roth, Thomas
Médium: Artigo
Jazyk:Inglês
Vydáno: American Academy of Sleep Medicine 2020
Témata:
Scientific Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970588/
https://ncbi.nlm.nih.gov/pubmed/32351205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5664/jcsm.8526
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky